Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Altamira Therapeutics Ltd (CYTO)

Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Altamira Therapeutics Ltd CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM 11 BMU

https://altamiratherapeutics.com Employees: 12 P: 441-295-5950

Description:

Altamira Therapeutics Ltd. is dedicated to developing therapeutics which addresses unmet medical needs. The Company is currently active in the development of RNA therapeutics for extrahepatic therapeutic targets, nasal sprays for protection against airborne viruses and allergens or the treatment of vertigo and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss. Altamira Therapeutics Ltd., formerly known as Auris Medical Holding Ltd., is headquartered in Hamilton, Bermuda.

Key Statistics

Overview:

Market Capitalization, $K 1,439
Enterprise Value, $K 749
Shares Outstanding, K 3,401
Annual Sales, $ 0 K
Annual Net Income, $ -4,310 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,723 K
EBIT, $ 0 K
EBITDA, $ -6,460 K
60-Month Beta 1.81
% of Insider Shareholders 13.03%
% of Institutional Shareholders 1.91%
Float, K 2,958
% Float 86.97%
Short Volume Ratio 0.37

Growth:

1-Year Return -92.93%
3-Year Return -99.94%
5-Year Return -99.93%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 99.72%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 09/24/24
Earnings Per Share ttm 0.00
EPS Growth vs. Prev Year -81.75%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 12/13/23

CYTO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.16
Book Value/Share 2.82
Interest Coverage -3.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar